Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Besponsa patent expiry date usa?

See the DrugPatentWatch profile for Besponsa

What is Besponsa’s (inotuzumab ozogamicin) patent expiry date in the USA?

Publicly available information on an exact “Besponsa patent expiry date” in the USA isn’t straightforward to give from the brand name alone, because patent expiration depends on the specific patent(s) listed for Besponsa, their jurisdictional scope, and whether you mean ordinary patent expiration, pediatric exclusivity extensions, or market exclusivity under FDA rules.

If you tell me whether you mean:
- the earliest patent expiration,
- the latest patent expiration,
- or the expiry of FDA/market exclusivity (not the same as a patent),
I can narrow the answer to the right kind of date.

How do I find Besponsa’s real patent expiry date in the USA (practical method)?

In the US, the most reliable way to get the patent expiration timeline for a specific drug is to check FDA’s Orange Book record for Besponsa (active ingredient: inotuzumab ozogamicin). The Orange Book lists:
- relevant patents,
- their expiration dates (and sometimes other events),
- and exclusivity periods that can delay generic/biosimilar approval even after some patents expire.

A common approach is to look at the Orange Book entry and identify the “last” relevant patent expiration date tied to the product.

Is Besponsa a small-molecule generic scenario or a biosimilar scenario?

Besponsa is a biologic (an antibody-drug conjugate), so competition usually comes through biosimilar pathways rather than the “generic small-molecule” model. That matters because biosimilar development timing can depend on both patent status and FDA exclusivity, not only one single patent date.

Why you might see multiple dates (earliest vs latest) for “expiry”

Even for one brand drug, you can see multiple expiration dates because different patents cover different aspects (for example, composition, method of use, or manufacturing). The “expiry date” a company cares about is often the latest expiration of the patents that block approval of a competing product, not the first one to expire.

What I need from you to give an exact date

Send either:
1) the Orange Book “Patent/Exclusivity” table you’re looking at (or a link/screenshot), or
2) the exact Besponsa product details you mean (dose/form, and whether you mean “patents only” or “patents + exclusivity”).

Then I can interpret the Orange Book listing and tell you the specific USA patent expiry date you’re asking for (earliest, latest, or exclusivity end date).

Sources

No sources were provided in the prompt, so I can’t cite an exact USA expiry date yet. If you paste the Orange Book section (or link it), I’ll respond with the exact expiry date(s) and citations.



Other Questions About Besponsa :

Is besponsa effective for all? How does Besponsa treat relapsed ALL?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI-generated claim is fully supported by the cited FDA label sections (5.1 and 5.2) and the dosage modification requirement in 2.3, with no contradictions or unsafe omissions identified relative to the stated claim.


Category Scores

Dosage
100
Excellent
Dosage
100
Excellent

Accurate Statements

BESPONSA has increased risk of hepatotoxicity including hepatic VOD.
Supported by label section 5.1 (hepatotoxicity including VOD).
BESPONSA has increased post-HSCT non-relapse mortality.
Supported by label section 5.2 (higher post-HSCT non-relapse mortality in the BESPONSA arm).
VOD and infections are common causes of post-HSCT non-relapse mortality.
Supported by label section 5.2 (most common causes included VOD and infections).
Permanent discontinuation is required for VOD or other severe liver toxicity.
Supported by label section 2.3 (VOD or other severe liver toxicity — permanently discontinue treatment).

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
No unsupported or contradictory safety statements were made; the claim correctly reflects labeled warnings/precautions and the labeled discontinuation action for VOD/severe liver toxicity.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
57
Visibility
64
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • Patent expiration depends on the specific patent(s) listed for Besponsa and related FDA exclusivity rules
  • The most reliable way is to check FDA’s Orange Book record for Besponsa (active ingredient: inotuzumab ozogamicin)
  • Besponsa is a biologic (an antibody-drug conjugate), so competition usually comes through biosimilar pathways
Differentiators
  • Explains timelines require Orange Book patents and FDA exclusivity (not just a single patent date)
  • Frames Besponsa as a biologic/antibody-drug conjugate rather than a small-molecule generic

Pricing Perception: Not Mentioned